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Abstract
Background: In patients with acute stroke, increased body temperature is associated with large
lesion volumes, high case fatality, and poor functional outcome. A 1°C increase in body
temperature may double the odds of poor outcome. Two randomized double-blind clinical trials in
patients with acute ischemic stroke have shown that treatment with a daily dose of 6 g
acetaminophen (paracetamol) results in a small but rapid and potentially worthwhile reduction of
0.3°C (95% CI: 0.1–0.5) in body temperature. We set out to test the hypothesis that early
antipyretic therapy reduces the risk of death or dependency in patients with acute stroke, even if
they are normothermic.
Methods/design: Paracetamol (Acetaminophen) In Stroke (PAIS) is a randomized, double-blind
clinical trial, comparing high-dose acetaminophen with placebo in 2500 patients. Inclusion criteria
are a clinical diagnosis of hemorrhagic or ischemic stroke and the possibility to start treatment
within 12 hours from onset of symptoms. The study will have a power of 86% to detect an absolute
difference of 6% in the risk of death or dependency at three months, and a power of 72% to detect
an absolute difference of 5%, at a 5% significance level.
Discussion: This is a simple trial, with a drug that only has a small effect on body temperature in
normothermic patients. However, when lowering body temperature with acetaminophen does
have the expected effectiveness, 20 patients will have to be treated to prevent dependency or death
in one.
Background
In patients with acute stroke, increased body temperature
is associated with high case fatality and poor functional
outcome [1]. In the observational Copenhagen Stroke
study, a 1°C increase in body temperature measured
within 12 hours after stroke onset doubled the odds of
poor outcome. The relation between body temperature
and outcome was not affected by severity of symptoms at
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gests that even a small reduction in body temperature in
acute stroke could improve outcome.
Phase II studies
We conducted two randomized, placebo-controlled clini-
cal trials to study whether early treatment with acetami-
nophen reduces body temperature in patients with acute
ischemic stroke confined to the carotid territory. In the
first trial, seventy-six patients were randomized to daily
treatment with either 3000 or 6000 mg acetaminophen,
or placebo. In the high-dose group this resulted in a 0.4°C
(95% CI: 0.1 to 0.7°C) lower body temperature than pla-
cebo treatment at 24 hours after onset [7]. The second trial
was conducted to study the effect of ibuprofen and to con-
firm the effect of high-dose acetaminophen on body tem-
perature. Seventy-five patients with acute ischemic stroke
of the anterior circulation were randomized to daily treat-
ment with either 2400 mg ibuprofen, 6000 mg acetami-
nophen, or placebo during 5 days [8]. Treatment with
high-dose acetaminophen resulted in a 0.3°C reduction
(95% CI: 0.0 to 0.6°C) in body temperature at 24 hours
compared to treatment with placebo [9]. A pooled analy-
sis of the data from both studies showed that a significant
decrease of body temperature occurred within 4 hours
after start of treatment with high-dose acetaminophen
[10]. These studies suggest that high-dose acetaminophen
can induce a small, but early reduction in body tempera-
ture in patients with acute stroke.
Pharmacological properties and toxicity of 
acetaminophen
Acetaminophen is a potent inhibitor of prostaglandin
production within the central nervous system. This pre-
sumably accounts for its analgesic and antipyretic proper-
ties. It is rapidly absorbed through the gastrointestinal
tract and uniformly distributed through most body fluids.
After oral administration peak plasma levels are reached
after 30 minutes to 1 hour [11]. Rectal administration
may lead to a slightly slower absorption, but effective
plasma levels are reached after approximately one hour
[12]. Acetaminophen is mainly conjugated in the liver,
and then excreted in the urine. Plasma half-life is 1.5 to 3
hours. Following a dose of 140 mg/kg bodyweight or
more, the glucuronide pathway may become saturated,
and (hepato-) toxicity may result. In the above-mentioned
pilot trials, acetaminophen in a dose of 6 g/day was not
associated with hepatotoxicity or other side effects [7,9].
Aim and purpose of the study
In guidelines for the treatment of acute ischemic or hem-
orrhagic stroke, antipyretic therapy is recommended in
patients who develop fever [13,14]. This recommendation
is based on expert opinion and observational studies but
not on randomized clinical trials. Because observational
studies suggest that every decrease in body temperature,
regardless of the initial body temperature, is potentially
benificial, antipyretic therapy may even improve outcome
in patients without fever. The aim of PAIS is to test
whether early antipyretic treatment with acetaminophen
in a daily dose of 6000 mg for a period of 3 days will
improve functional outcome in patients with acute stroke,
even if they are normothermic.
Methods
Study design
PAIS is a multicenter, double-blind, placebo-controlled
clinical trial that aims to include 2500 patients with acute
stroke. The statistical analysis will be performed on an
intention-to-treat basis [15]. Publication of the study
results will be on behalf of the PAIS investigators.
Study medication
Patients will be treated for 3 days with acetaminophen in
a daily dose of 6 times 1000 mg, or matching placebo. The
study medication will be administered through identical
tablets. The study medication will be provided in white
paper boxes, numbered consecutively with a medication
number. Each box contains 40 identical tablets of aceta-
minophen 500 mg, or placebo, and one suppository of
acetaminophen 1000 mg, or placebo. Every gift of medi-
cation consists of 2 tablets except the first gift, which can
be given as a suppository. The suppository can be admin-
istered at the discretion of the treating physician, for
example when a patient has swallowing difficulties but
has not yet been given a nasogastric tube.
Inclusion- and exclusion criteria
Inclusion criteria are a clinical diagnosis of ischemic
stroke or primary intracerebral hemorrhage, the possibil-
ity to confirm the diagnosis with CT or MRI within 24
hours after inclusion in the study, the possibility to start
treatment within 12 hours from onset of symptoms (for
patients who noticed symptoms after waking from sleep,
the time last seen well is taken as the time of onset of
symptoms), age over 18 years, and signed informed con-
sent.
Exclusion criteria are body temperature of less than
36.0°C or more than 39.0°C, a history of liver disease or
elevated liver enzymes (ASAT, ALAT, AP, or gamma-GT)
to more than twice the upper limit of normal, a history of
alcohol abuse, hypersensitivity to acetaminophen, death
appearing imminent at the time of inclusion, and any pre-
stroke impairment that has led to dependency (modified
Rankin scale (mRS) > 2) and therefore interferes with the
assessment of functional outcome.Page 2 of 7
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Patients will be assigned to treatment with acetami-
nophen 1000 mg, 6 times daily, or to matching placebo,
for three days. Treatment assignment will be random. The
study medication will be packed in separate boxes with a
unique number. The study number is printed on an adhe-
sive label, to be put on the inclusion form.
The study numbers correspond to those on a computer-
generated list with the assigned treatment. An independ-
ent statistician, who is not involved in the study, will pro-
vide the list. The pharmacist of each center will receive a
list that indicates the treatment allocation for each rand-
omized patient.
Safety concerns and adverse events
Local investigators are advised to be careful not to over-
look infections in patients who are treated according to
the study protocol and might be treated with acetami-
nophen. Therefore, treating physicians are advised to
lower their threshold for clinical suspicion of infection,
and to start diagnostic studies and antibiotic treatment
earlier than usual.
Serious adverse events will be reported by the local inves-
tigator to the PAIS trial office and include any infection
that leads to prolonged hospital stay or is life threatening,
death from any cause, liver failure, and gastro-intestinal
hemorrhage that occurs during hospitalization and within
the first 14 days after randomization.
Outcomes
The primary outcome measure will be functional out-
come, as determined by the score on the modified Rankin
scale (mRS) at 3 months [16]. Outcome will be dichot-
omized and defined as good (mRS 0 to 2) or poor (mRS 3
to 6). Other outcome measures will include an alternative
dichotomization of the mRS (0 to 3 versus 4 to 6), the
score on the Barthel index (BI) at 3 months [17], and body
temperature at 24 hours from start of treatment. In addi-
tion, quality of life will be measured at three months with
the EuroQol-5D [18,19].
Design
Time path
The study will run for four years. Patient inclusion will
continue during the first 3.5 years. Three months will be
needed to conclude the follow-up, and three months to
run the final analysis and prepare the final report. In order
to include 2500 patients in the study within the given
timeframe, an annual recruitment rate of more than 700
patients will have to be realized.
Study activities
Day 0 is defined as the time period between onset of
stroke and inclusion in the study. All baseline investiga-
tions are therefore carried out on day 0, except for the CT
or MRI scans, which may be done within 24 hours after
inclusion into the study. Day 1 commences directly after
inclusion into the study. All time periods in the study are
measured relative to the time of the start of treatment.
Baseline data
At baseline the medical history, including previous strokes
or TIAs, will be assessed and a general and neurological
examination will be carried out. The National Institutes of
Health stroke scale (NIHSS) is used to assess stroke sever-
ity at inclusion in the study [20]. Laboratory investiga-
tions will include a full blood count, glucose, electrolytes,
creatinine, and liver enzymes: ALAT, ASAT, AP, and
gamma-GT. A brain CT or MRI will be done within 24
hours after inclusion in the study. Body temperature (tym-
panic or rectal) will be measured at inclusion, and 24
hours later. In each individual patient, the mode of ther-
mometry at 24 hours will be similar to that at baseline.
After completing the one-page inclusion form, the local
investigator will send it by fax to the trial office. The data
will be automatically added to the study database by
means of optical character recognition soft- and hardware
(Teleform, Verity Inc. Sunnyvale, U.S.A.). All data entries
will be verified by a study assistant. The trial coordinator
will compare the data provided by the local investigators
with those in the source documents in a random sample
of at least 10% of the patients.
Day 14 or discharge
After 14 days or at discharge, if earlier, the discharge des-
tination, the number of remaining tablets and supposito-
ries, and functional status (BI) will be assessed. Based on
the neurological examination and the results of CT, ECG,
duplex, and other studies, etiological stroke type will be
assessed according to the TOAST classification [21]. Seri-
ous adverse events that occurred during 14 days after start
of treatment will be recorded.
Three month follow-up
Functional outcome at three months (mRS, BI) and qual-
ity of life (EuroQol-5D) will be assessed by telephone
interview with the patients themselves or their caregivers.
The telephone interview will be conducted by the central
trial office.
Data analysis
The data will be analyzed on an intention-to-treat basis. In
the analysis the occurrence of the primary outcome
(mRS>2) will be compared between the two treatment
arms by computing the relative risk, expressed as a riskPage 3 of 7
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the power of the study, adjustments will be made with
multiple logistic regression for any imbalance in the fol-
lowing prognostic variables: time since onset, baseline
temperature, stroke severity, stroke type (hemorrhagic ver-
sus ischemic), ischemic stroke subtype (lacunar versus
non-lacunar), and thrombolytic therapy, as suggested by
Hernandez [22].
The treatment effect will be evaluated in specific sub-
groups, i.e. in patients treated early (i.e. within 9 hours
from onset), in patients with ischemic stroke (as opposed
to hemorrhagic stroke), and in patients with non-lacunar
ischemic stroke.
Interim analysis of safety and effectiveness
During the period of recruitment into the study, every year
interim analyses of in-hospital mortality and of any other
information that is available on major outcome events
including serious adverse events believed to be due to
treatment will be supplied, in strict confidence, to the
chairman of the data monitoring committee, along with
any other analyses that the committee may request. In the
light of these analyses, the data monitoring committee
will advise the chairman of the steering committee if, in
their view, the randomized comparisons in PAIS have pro-
vided both: 1) proof beyond reasonable doubt that for all,
or for some, specific types of patients, one particular treat-
ment is clearly indicated or clearly contra-indicated in
terms of a net difference in mortality, and 2) evidence that
might reasonably be expected to influence materially the
patient management of the many clinicians who are
already aware of the results of other main trials. The steer-
ing committee can then decide whether to modify intake
to the study (or to seek extra data). Unless this happens,
however, the steering committee, the collaborators, and
the central administrative staff (except those who produce
the confidential analyses) will remain ignorant of the
interim analyses. Appropriate criteria of "proof beyond
reasonable doubt" cannot be specified precisely, but some
members of the committee have expressed sympathy with
the view that a difference of at least 3 standard deviations
in an interim analysis of a major outcome event may be
needed to justify halting, or modifying such a study pre-
maturely. If this criterion were to be adopted, it would
have the practical advantage that the exact number of
interim analyses would be of little importance, and so no
fixed schedule is proposed.
Collaborators, and all others associated with the study,
may write through the PAIS trial-office in Rotterdam to
the chairman of the data monitoring committee, drawing
attention to any worries that they may have about the pos-
sibility of particular side-effects, or about particular cate-
gories of patients requiring special consideration, or
about any other matters that may be relevant [23].
Sample size
In the Copenhagen Stroke Study, the odds ratio of poor
outcome increased by a factor of 2.2 (95% CI: 1.4 to 3.5),
with each degree Celsius increase in body temperature
[5,24]. We expect that 50% of the patients assigned to pla-
cebo will have a poor outcome at three months [7,9,10].
A relative odds reduction with a factor of 2.2 per degree
Celsius of body temperature would imply an absolute
reduction in poor outcome of 18.75%. A 0.3°C reduction
in body temperature would then theoretically lead to a
6% absolute or 12% relative reduction of poor outcome.
Two thousand five hundred patients (1250 in each arm)
will provide a power of 86% to detect at least such an
effect, and a power of 72% to detect an absolute reduction
of 5%.
Discussion
Several studies have demonstrated a strong relationship
between an increased body temperature in the first hours
after stroke and poor functional outcome [3,5,24-26]. To
date, it is still unclear whether this relationship is causal.
Some authors suggest that increased body temperatures
after stroke are just an epiphenomenon of extensive cere-
bral damage and, thereby, of poor outcome. In a recent
study of 725 consecutive patients admitted within 6 hours
from the onset of acute ischemic stroke, no relation was
found between initial body temperature and outcome
[27]. The authors used a rather insensitive method of sta-
tistical analysis (Spearman correlation and comparison of
median modified Rankin scale scores with a nonparamet-
ric test). All patients with a body temperature of 37.0°C
were treated with acetaminophen. Consequently, the
results of this study should be interpreted with care.
In the Copenhagen Stroke study, the relationship between
body temperature and outcome remained present after
adjustment for initial stroke severity [5]. Furthermore,
early body temperature measurements (within the first 6
hours) seemed to be more strongly related to outcome
than later measurements [24]. This suggests that the rela-
tionship with poor outcome is not confounded by the
occurrence of secondary infections, such as pneumonia or
urinary tract infection, because these usually appear later
in the course of the disease. Arguments for a causal rela-
tionship stem from the observation that the effect of body
temperature on outcome is independent of the size of the
brain lesion and from the beneficial effect of temperature-
lowering treatment on infarct volume in animal models.
Animal studies have demonstrated that higher body tem-
peratures may worsen ischemic damage through an
increase of blood-brain-barrier permeability and
increased metabolic demands, resulting in acidosis andPage 4 of 7
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a recent meta-analysis of controlled animal studies on the
effect of hypo- and hyperthermia in focal cerebral
ischemia, Miyazawa showed that hyperthermia increases
infarct volume whereas hypothermia reduces infarct vol-
ume [29]. These reproducible observations from observa-
tional clinical studies and animal experiments strongly
suggest that hypothermia may be a potent neuroprotec-
tive intervention, but this has never been studied in ade-
quately powered clinical trials.
Randomized clinical trials of hypothermia in brain injury
and hypoxic brain damage have provided conflicting
results. In patients with coma after closed head injury,
treatment with hypothermia, with body temperature
reaching 33°C within eight hours after injury, was not
effective in improving outcome [30]. In patients who had
been successfully resuscitated after cardiac arrest, hypo-
thermia with body temperatures between 32°C and 34°C
increased the chances of favorable outcome and reduced
mortality [31,32]. Perhaps the lack of effect in traumatic
brain injury can be explained by the abundant presence of
direct, i.e. non-ischemic damage.
Other methods of body temperature reduction
The feasibility of different methods of reducing body tem-
perature in patients with acute stroke has been studied in
several pilot studies.
A case-control study was conducted in 74 patients (17
cases, 56 controls) to assess the feasibility and safety of
reducing body temperature to approximately 35.5°C with
cooling blankets in combination with pethidine to pre-
vent shivering [33].
Another study on the feasibility of several methods of
lowering body temperature was conducted in eight
patients. Two patients were treated with 1 gram acetami-
nophen at 4-hour intervals. Two patients were cooled
with cooling blankets, in two patients sponging with 70%
alcohol was applied, and 2 patients served as a control
group and were only monitored. Target temperature
reductions of 1°C were reached within 6 hours [34].
A study in 50 patients with a severe middle cerebral artery
infarct demonstrated that body temperature can be
reduced to 32 to 33°C, with the use of cooling blankets,
alcohol and ice bags, under complete anesthesia [35]. The
procedure had many side effects; the most frequent com-
plications were thrombocytopenia (70%), bradycardia
(62%), and pneumonia (48%).
The many complications that occurred in the study of
Schwab can be explained by the fact that these patients all
had severe middle cerebral artery infarcts. In the remain-
ing studies safety concerns were less prominent.
The COOL-AID study was a randomized controlled study
of endovascular cooling to 33°C compared to standard
medical treatment in 40 patients with acute ischemic
stroke. Shivering was suppressed by warming blankets
and sedatives [36].
Most studies showed that cooling using the different
methods was feasible, although it was more labor intense
in the more invasive methods that induced larger body
temperature decreases. However, in the COOL-AID study
the feasibility was poor: 5 of the 18 treated patients did
not reach the target temperature.
Mild reductions in body temperature – around 1°C – can
be reached with external cooling blankets and general
measures, within six hours, or more rapidly with an
endovascular temperature management system. This
approach requires mild sedation or morfine to reduce
shivering, may be uncomfortable to patients, and is labor
intensive. More aggressive approaches require anesthesia,
and may induce increased risk of pulmonary- and other
complications. This suggests that there is a need for a sim-
ple, medical intervention that may reduce body tempera-
ture to a lesser extent, but is cheap and safe.
Ethical considerations
Observational studies have shown an association between
an increased body temperature and a poor outcome. Sev-
eral national and international guidelines suggest that
raised body temperature in stroke patients should be
treated [13]. However, the efficacy of temperature-lower-
ing treatment to improve functional outcome has not yet
been demonstrated in randomized trials [37]. This
dilemma is the rationale for PAIS.
PAIS: a simple trial
PAIS is a large, randomized, multi-center clinical trial. To
keep the threshold for including patients low, the study
design has been kept simple. The amount of data to be
gathered is therefore limited; it consists of two one-page
forms, one to be filled out at inclusion and one to be filled
out at discharge. The local investigator will keep a log of
randomized patients. The 3-month follow-up will be con-
ducted by telephone from the central trial office. New
centers are welcome to join the trial.
Conclusion
The PAIS trial will test the efficacy of a modest tempera-
ture reduction by high-dose acetaminophen to improve
functional outcome after stroke. The treatment strategy
tested is cheap and safe. When lowering body temperature
with acetaminophen will have the expected effectiveness,Page 5 of 7
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